- Recruiting
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
Updated: Sep 27, 2022
Multiple Myeloma Research Consortium
MyDRUG
RRMM
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium
MMRC
MMRF
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm.
The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).
Sponsor
Multiple Myeloma Research Consortium
Collaborators
AbbVie
Celgene Corporation
Eli Lilly and Company
Genentech, Inc.
Janssen, LP
Takeda
GlaxoSmithKline
Karyopharm Therapeutics Inc
Multiple Locations
ClinicalTrials.gov Identifier: NCT03732703
Official Title: Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
First Posted : November 7, 2018
Click here for details on ClinicalTrials.gov
Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomide
Drug: Enasidenib, dexamethasone, ixazomib, pomalidomide
Drug: Cobimetinib, dexamethasone, ixazomib, pomalidomide
Drug: Erdafitinib, dexamethasone, ixazomib, pomalidomide
Drug: Venetoclax, dexamethasone, ixazomib, pomalidomide
Drug: Daratumumab, dexamethasone, ixazomib, pomalidomide
Drug: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide
Drug: Selinexor, dexamethasone, ixazomib, pomalidomide
The Multiple Myeloma Research Consortium® (MMRC®)
What is the MMRC®?
https://themmrf.org/finding-a-cure/our-work/mmrc/
What is the MyDRUG study?
https://themmrf.org/finding-a-cure/our-work/my-drug/
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
NCT03657251: MMRF CureCloud Research Initiative
https://www.themyelomaclinicaltrials.com/single-post/nct03657251-mmrf-curecloud-research-initiative
- Multiple locations
- Arizona: Mayo Clinic Arizona
- California: City of Hope Duarte
- Georgia: Emory University Atlanta
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Massachusetts: Massachusetts General Hospital Boston
- Minnesota: Mayo Clinic Rochester Minnesota
- Missouri: Washington University School of Medicine Saint Louis
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New Jersey: Hackensack University Medical Center
- North Carolina: Levine Cancer Institute Charlotte
- Texas: UT Southwestern Medical Center Dallas
Locations
United States, Arizona
United States, California
United States, Georgia
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Texas